

SANGAMO BIOSCIENCES INC  
Form 8-K  
June 03, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT**  
**TO SECTION 13 OR 15(D) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): May 29, 2015**

**SANGAMO BIOSCIENCES, INC.**  
**(Exact Name of Registrant as Specified in Its Charter)**

**Delaware**  
**(State or Other Jurisdiction of Incorporation)**

**000-30171**  
**(Commission File Number)**

**68-0359556**  
**(IRS Employer Identification No.)**

**501 Canal Blvd**  
**(Address of Principal Executive Offices)**

**(510) 970-6000**

**Richmond, California 94804**  
**(Zip Code)**

**(Registrant's Telephone Number, Including Area Code)**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.**

On May 29, 2015, Dr. Philip D. Gregory, senior vice president, research and chief scientific officer, resigned from Sangamo BioSciences, Inc. (the Company). Dr. Gregory's responsibilities are being assumed by other vice presidents in the research group, who will now report to Dr. Geoff Nichol, executive vice president, research and development. The Company does not have any immediate plans to fill this position. This departure does not impact the Company's existing guidance regarding its clinical development programs.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DATE: June 3, 2015

SANGAMO BIOSCIENCES, INC.

By: /s/ Edward O. Lanphier II  
Edward O. Lanphier II  
President, Chief Executive Officer